Mekinist
Named-patient access overview. Mekinist is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Mekinist (trametinib) is an oral MEK1 and MEK2 kinase inhibitor approved by the US Food and Drug Administration in May 2013, originally as monotherapy for BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. Subsequent FDA actions extended the label to combination use with dabrafenib (Tafinlar) for BRAF V600-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, and BRAF V600E-mutant solid tumors (tissue-agnostic) in adult and pediatric patients. The manufacturer is approximately Novartis.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Mekinist
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Mekinist is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Mekinist in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Mekinist
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.